Transatlantic tensions and the R&D debate
This article was originally published in SRA
Executive Summary
On 14 September, Europe's Innovative Medicines Initiative, which aims to find ways of streamlining the drug development process, will hold a press conference to present its achievements to date. Approved at the end of December 2007, the IMI is a joint effort between the European Union and the European industry federation EFPIA that is expected to improve the productivity of pharmaceutical and biotech R&D and give companies a keener competitive edge.